glp-1 obesity drug news today oct 23 2025 Use of diabetes and anti-obesity drugs surges nationwide GLP-1 Market Industry Trends and

Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications

Research on growth hormone's neuroprotective properties suggests potential applications beyond cognitive enhancement

Recent insights into alteration of red blood cells by Babesia bovis : moovin forward

GLP-1 receptor agonists were associated with a significantly reduced risk of new fibroid onset compared to metformin, specifically among patients who received at least two doses of medication

It has no palm olein oil, no corn syrup, no artificial growth hormones, and it is non-GMO

[DOI] [PMC free article] [PubMed] [Google Scholar] 149.Romero-Gmez M., Lawitz E., Shankar R.R., Chaudhri E., Liu J., Lam R.L.H., Kaufman K.D., Engel S.S